DIA will host Pharmacovigilance and Risk Management Strategies 2011 from January 9-12, 2011 in Washington, DC.
This comprehensive three-day program will discuss the current complexities and controversies in pharmacovigilance and risk management throughout all phases of development and marketed use. Sessions will include:
• Pharmacovigilance and Medical Product Safety: International Perspectives
• Analysis of Health Care
• Pharmacovigilance and Medical Product Safety: US Perspectives
• Early Understanding of Clinical Safety and Risk
• Drug Safety and Pharmacovigilance Inspections: FDA, European Union, and Japanese Approaches
• Current Approaches to Pharmacovigilance and Risk Management
• Safety Consideration When Developing a Proprietary Name
Nancy J. Norton, President, International Foundation for Functional Gastrointestinal Disorders, will deliver the keynote presentation titled, “Impact of Risk Management Programs: Patient Perspective.”
“Clinical trial safety and postmarketing pharmacovigilance is more critical than ever in the development and evaluation of the safe use of marketed medical products,” says Program Co-chair Annette Stemhagen, DrPH, FISPE, Senior Vice President, Safety, Epidemiology, Registries, and Risk Management, United BioSource Corporation. “This conference will explore how to crate and utilize risk management strategies to create an effective organizational ‘system.’”
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related healthcare products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well-being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.